Abiraterone, Orteronel, Enzalutamide and Docetaxel: Sequential or Combined Therapy?

ABSTRACT: Objective: To summarize the current therapeutic status using chemotherapeutic agent docetaxel and endocrine therapeutic agents (ARAT, abiraterone, orteronel or enzalutamide) for the treatment of metastatic castration-resistant prostate cancer (mCRPC), including sequential therapy and combined therapy, to promote the consensus on the optimal regimen for achieving superior treatment efficacy. Methods: Through literature search in PubMed, articles with the following relevant keywords were collected and anlyzed: CRPC, abiraterone, orteronel and enzalutamide, median survival, overall survival, prostate specific antigen (PSA), PSA response rate and median radiologic progression-free survival. Results: Fifty-eight articles were obtained and analyzed in this review. These arti

SUBMITTER: Chen MK 

PROVIDER: S-EPMC8891580 | biostudies-literature | 2022

REPOSITORIES: biostudies-literature